Breaking News Instant updates and real-time market news.

AMED

Amedisys

$55.31

0.93 (1.71%)

, LHCG

LHC Group

$61.86

1.38 (2.28%)

13:01
12/18/17
12/18
13:01
12/18/17
13:01

Home health-care providers fall on report of potential Humana-Kindred deal

Shares of home health companies Amedisys (AMED), LHC Group (LHCG) and Almost Family (AFAM) are all down following a report that Humana (HUM) is in talks to buy Kindred Health (KND). HUMANA, KINDRED TALKS: Humana is in advanced talks to join private equity firms Welsh Carson Anderson & Stowe and TPG in a deal to acquire Kindred Healthcare that would value the company at $9 per share, the Wall Street Journal reported on Sunday. As part of the deal, Kindred, which has a market value of roughly $750M, would be split up, with Welsh, Carson, Anderson & Stowe and TPG taking over its facility-focused business and the private equity firms along with Humana would acquire its home- and hospice-care operations. The move comes as Humana looks to expand its home-health operations to improve care and reduce costs. DEUTSCHE SAYS SALE PRICE 'LOW': Deutsche Bank analyst Chris Rigg said that the news of the deal is unsurprising as Humana has voiced interest in acquiring home health businesses, and Welsh, Carson is a member of Select Medical's (SEM) board and has done deals with them in the past. Rigg said that while he's Hold rated on Kindred Healthcare, he views the reported sale price of $9 per share as "too low." The analyst noted that his sum-of-the-parts analysis has Kindred valued at $15 per share, or a 79% premium to Friday's close and 71% premium to the takeout price reported this weekend. RBC SAYS DEAL "NOT SURPRISING": RBC Capital analyst Frank Morgan also said it is "not surprising" to see the report that Humana and partner private equity firms are in talks to take over Kindred Healthcare's home health and hospice business, while the firms would retain the long-term acute care and rehab business. He noted that such a deal would complement Humana's existing home health footprint and be similar to recent vertical integration moves by managed care organization rivals Aetna (AET) and UnitedHealth (UNH). Morgan has a Sector Perform rating on Kindred shares. PRICE ACTION: Amedisys fell 6% to $52.02, LHC Group dropped 2.1% to $60.57 and Almost Family fell 2.7% to $55.45 in afternoon trading, while Kindred rose 6.4% to $9.10. Humana declined 2% to $248.53.

AMED

Amedisys

$55.31

0.93 (1.71%)

LHCG

LHC Group

$61.86

1.38 (2.28%)

AFAM

Merged with LHCG

$57.00

0.6 (1.06%)

HUM

Humana

$247.94

-5.7 (-2.25%)

KND

Kindred Healthcare

$9.10

0.5 (5.81%)

SEM

Select Medical

$16.50

-0.15 (-0.90%)

AET

Aetna

$178.86

-0.84 (-0.47%)

UNH

UnitedHealth

$222.58

0.7597 (0.34%)

  • 20

    Dec

AMED Amedisys
$55.31

0.93 (1.71%)

11/09/17
BNCH
11/09/17
DOWNGRADE
BNCH
Hold
Amedisys downgraded to Hold from Buy at Benchmark
Benchmark analyst Bill Sutherland downgraded Amedisys to Hold from Buy as he believes the company's improving fundamentals are now reflected in the stock after its 25% advance since last week's CMS decision to not pursue an onerous rate proposal for 2019. He contends that Amedisys' valuation is now at an appropriate premium to its peer group.
11/09/17
CHLM
11/09/17
NO CHANGE
Target $68
CHLM
Buy
Amedisys price target raised to $68 from $55 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich raised his price target for Amedisys to $68 from $55 following "solid" Q3 results and as Home Health is about to turn the corner. The analyst reiterates a Buy rating on the shares.
11/22/17
11/22/17
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Nutanix (NTNX) initiated with a Buy at Needham. 2. Regenxbio (RGNX) and Sangamo (SGMO) were initiated with an Overweight at Barclays. 3. Amedisys (AMED), HealthSouth (HLS), LHC Group (LHCG), and LifePoint (LPNT) were initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/21/17
WBLR
11/21/17
INITIATION
WBLR
Outperform
Amedisys initiated with an Outperform at William Blair
William Blair started Amedisys with an Outperform rating.
LHCG LHC Group
$61.86

1.38 (2.28%)

11/17/17
OPCO
11/17/17
NO CHANGE
Target $85
OPCO
Outperform
LHC Group price target raised to $85 from $80 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for LHC Group (LHCG) to $85 saying the merger with Almost Family (AFAM) is "highly favorable" given its strategic and financial benefits. The analyst continues to be a buyer of the shares at current levels. He notes that the all-stock nature of the transaction preserves LHC's balance sheet for additional acquisition opportunities going forward. Wiederhorn keeps an Outperform rating on the shares.
11/21/17
WBLR
11/21/17
INITIATION
WBLR
Outperform
LHC Group initiated with an Outperform at William Blair
William Blair started LHC Group with an Outperform rating.
11/20/17
RBCM
11/20/17
DOWNGRADE
Target $62
RBCM
Sector Perform
Almost Family downgraded to Sector Perform at RBC Capital after LHC mergerLHC Group
As noted earlier, RBC Capital analyst Frank Morgan downgraded Almost Family (AFAM) to Sector Perform from Outperform but raised his price target to $62 from $54 to reflect the implied pricing of the merger announced last week. Morgan says the stock-for-stock transaction with LHC Group (LHCG) is positive, creating the largest in-home service provider in the industry. The analyst also notes that given the low overlap in the two companies' operations, he does not anticipate any antitrust issues related to the merger.
AFAM Merged with LHCG
$57.00

0.6 (1.06%)

11/20/17
RBCM
11/20/17
DOWNGRADE
RBCM
Sector Perform
Almost Family downgraded to Sector Perform from Outperform at RBC Capital
11/16/17
JPMS
11/16/17
NO CHANGE
JPMS
Neutral
Almost Family acquired for 16% premium, says JPMorgan
JPMorgan analyst Gary Taylor says Almost Family's (AFAM) merger of equals with LHC Group (LHCG) amounts to a takeover at a 16% premium, based on LHC's closing price yesterday. Regarding antitrust, the analyst notes that while the deal would propel the third and fourth largest players in the home-health industry to a number two position behind Kindred Healthcare (KND), the industry is "tremendously fragmented." Further, Taylor believes the merger agreement contains "onerous divestiture language." The analyst has a Neutral rating on Almost Family with a $59 price target.
HUM Humana
$247.94

-5.7 (-2.25%)

12/13/17
COWN
12/13/17
NO CHANGE
Target $285
COWN
Outperform
Cowen calls Humana a best idea for 2018, ups target to $285
Cowen analyst Christine Arnold raised her price target for Humana to $285 from $275 and names the stock a best idea for 2018. The analyst expects Medicare Advantage enrollment growth to accelerate in 2018 and believes a lower corporate tax rate could meaningfully benefit the company's earnings. She keeps an Outperform rating on Humana.
12/06/17
COWN
12/06/17
NO CHANGE
COWN
Tax reform best for Medicare Advantage products, says Cowen
Cowen analyst Christine Arnold reviewed the tax reform implications for the managed care sector and believes the lower tax rate will be most beneficial for Medicare Advantage products as it could allow companies to offset a portion of the non-tax deductible headwind, allowing for stronger margins and/or enhanced benefits for seniors. She believes the lower tax rate would be most positive for Molina (MOH) and WellCare (WCG) given their domestic exposure, but it would also lead to a 15% earnings increase above her projections for Aetna (AET), Anthem (ANTM), Centene (CNC) and Humana (HUM).
11/27/17
LEER
11/27/17
NO CHANGE
Target $280
LEER
Outperform
Cigna most likely acquirer of Humana in any potential transaction, says Leerink
Leerink analyst Ana Gupte notes that a Change of Control 8-K filed by Humana (HUM) suggests that the company is a possible take-out target after the Medicare Advantage Annual Enrollment Season, though the company maintains that this is a needed refresh with broader policy guidelines, rather than individually driven. The analyst sees Cigna (CI) as the most likely acquirer in any potential transaction and able to offer as much as 6% accretion in year 2 and 12% in year 3 post close. However, Anthem (ANTM) and even Wal-Mart (WMT) or Walgreens Boots Alliance (WBA) could be other dark horse acquirers, she contends. Gupte expects that Cigna would need to divest its legacy Health Spring MA assets to satisfy anti-trust regulators, with multiple possible buyers for the assets including WellCare (WCG), Aetna (AET) and Anthem. The analyst reiterates an Outperform rating and $280 price target on Humana shares.
12/18/17
RBCM
12/18/17
NO CHANGE
RBCM
Sector Perform
Report of possible Kindred-Humana deal not surprising, says RBC Capital
RBC Capital analyst Frank Morgan said it is "not surprising" to him to see The Wall Street Journal report that Humana (HUM) and partner PE firms are in talks to take over Kindred Healthcare's (KND) home health and hospice business, while the PE firms would retain the LTAC and rehab business. He notes that such a deal would complement Humana's existing home health footprint and be similar to recent vertical integration moves by MCO rivals Aetna (AET) and UnitedHealth (UNH). Morgan has a Sector Perform rating on Kindred shares.
KND Kindred Healthcare
$9.10

0.5 (5.81%)

11/20/17
STFL
11/20/17
UPGRADE
Target $7
STFL
Hold
Kindred Healthcare upgraded to Hold from Sell at Stifel
Stifel analyst Chad Vanacore upgraded Kindred Healthcare to Hold from Sell, stating that he expects the share price and earnings to remain volatile but much of the downside has been captured. The company's margins should be aided by the exit of its skilled nursing business, but Vanacore thinks additional significant cost savings will be needed to reach management's targets, he tells investors. He maintains a $7 price target on Kindred Healthcare shares.
12/18/17
DBAB
12/18/17
NO CHANGE
Target $9
DBAB
Hold
Kindred reported sale price of $9 per share is low, says Deutsche Bank
Deutsche Bank analyst Chris Rigg says that while he's Hold rated on Kindred Healthcare, the reported sale price of $9 per share to two private equity firms is low. The analyst notes that his sum-of-the-parts analysis has Kindred valued at $15 per share, or a 79% premium to Friday's close and 71% premium to the takeout price reported this weekend by the Wall Street Journal.
SEM Select Medical
$16.50

-0.15 (-0.90%)

01/30/17
WELS
01/30/17
DOWNGRADE
WELS
Market Perform
Select Medical downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Gary Lieberman downgraded Select Medical Holdings to Market Perform citing another "disappointing" quarter and his belief the company's 2017 EBITDA guidance will be difficult to achieve. The analyst lowered his price target range for the shares to $14-$16 from $15-$18.
11/06/17
DBAB
11/06/17
NO CHANGE
Target $22
DBAB
Buy
Select Medical selloff Friday 'hard to justify,' says Deutsche Bank
Deutsche Bank analyst Chris Rigg believes the 9% post-earnings selloff Friday in shares of Select Medical is "hard to justify." The miss and guide-down took the focus off of the most important takeaway, which was better than expected long-term acute care hospital results, Rigg tells investors in a research note. He sees "substantial upside" to long-term acute care hospital EBITDA from returning to pre-criteria occupancy levels, which management is targeting over the next 9-12 months. The analyst maintains a Buy rating on Select Medical with a $22 price target.
08/07/17
BARD
08/07/17
UPGRADE
BARD
Outperform
Select Medical upgraded to Outperform from Neutral at Baird
03/31/17
BNCH
03/31/17
INITIATION
Target $16
BNCH
Buy
Select Medical initiated with a Buy at Benchmark
Benchmark analyst Bill Sutherland initiated Select Medical with a Buy rating and $16 price target.
AET Aetna
$178.86

-0.84 (-0.47%)

12/12/17
SBSH
12/12/17
NO CHANGE
SBSH
Buy
Aetna removed from Focus List at Citi
Citi analyst Ralph Giacobbe removed Aetna (AET) from his firm's Focus List citing the pending takeover by CVS Health (CVS). The analyst sees no near-term catalysts but keeps a Buy rating on the shares.
12/15/17
12/15/17
UPGRADE
Target $81

Outperform
Express Scripts upgraded to Outperform on favorable 2018 setup at Baird
As previously reported, Baird analyst Eric Coldwell upgraded Express Scripts (ESRX) to Outperform from Neutral, saying that while he continues to have concerns about the PBM industry, the company's setup appears to be its most favorable in years. He believes the merger of CVS (CVS) and Aetna (AET) is unlikely to disrupt 2018-2019 performance and notes that the company's early tone on 2019 renewal and selling season was positive. Coldwell raised his price target on Express Scripts shares to $81 from $72.
12/06/17
FBCO
12/06/17
NO CHANGE
Target $195
FBCO
Neutral
Aetna price target raised to $195 from $174 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for Aetna (AET) to $195 from $174 based on a probability-weighted approach, with the analyst using a probability of roughly 70% that the Aetna-CVS (CVS) deal will be approved. Rice reiterates a Neutral rating on Aetna's shares.
12/18/17
WELS
12/18/17
NO CHANGE
WELS
Outperform
Aetna removed from Priority Stock List at Wells Fargo
Wells Fargo analyst Peter Costa removed Aetna (AET) from his firm's Priority Stock List based on its current definitive agreement with CVS (CVS) to be acquired for $145 per share in cash and 0.8378 share CVS per Aetna share. The analyst reiterates an Outperform rating on Aetna's shares.
UNH UnitedHealth
$222.58

0.7597 (0.34%)

12/05/17
BMOC
12/05/17
NO CHANGE
Target $200
BMOC
Market Perform
Aetna-CVS deal is a high risk-reward strategy, says BMO Capital
BMO Capital analyst Matt Borsch is positive on the Aetna (AET) - CVS Health (CVS) merger, saying it accelerates the transformation of healthcare offerings through "the shift to value-based reimbursement, formation of provider 'accountable care organizations', payer-side aggregation of provider assets, and proliferation of lower-cost sites of care" among others. Borsch says that while United Health (UNH) has led this path with Optum, CVS-Aetna partnership may challenge its model. The analyst keeps his Market Perform rating and $200 price target on Aetna, warning that a failed implementation, given the high debt loads and an uncharted path to convert storefronts to healthcare centers, might be "historic".
12/06/17
PIPR
12/06/17
NO CHANGE
Target $242
PIPR
Overweight
Piper likes UnitedHealth's path to vertical integration
While UnitedHealth's (UNH) $4.9B purchase of DaVita (DVA) subsidiary DaVita Medical Group is slightly higher than the $4B expected, the company's "unique value proposition driven by Optum can improve operations," Piper Jaffray analyst Sarah James tells investors in a research note. The analyst sees the deal as a "large cost-saving opportunity" and likes UnitedHealth's path of vertical integration. She keeps an Overweight rating on the shares with a $242 price target.
12/06/17
KEYB
12/06/17
NO CHANGE
KEYB
Sector Weight
DaVita received 'great price' for DMG unit, says KeyBanc
KeyBanc analyst Jason Gurda says DaVita (DVA) received a "great price" from UnitedHealth (UNH) for its DaVita Medical Group unit. The price for the "earnings growth-challenged" business is positive for DaVita shareholders and management noted that the proceeds will be used for significant stock repurchases, Gurda tells investors in a research note. He keeps a Sector Weight rating on DaVita shares.
12/14/17
RAJA
12/14/17
NO CHANGE
RAJA
Raymond James Analysts' Best Picks for 2018
Raymond James named its Analysts' Best Picks for 2018. They are: Alaska Air (ALK), Alibaba (BABA), Becton Dickinson (BDX), Broadcom (AVGO), Continental Resources (CLR), Dollar Tree (DLTR), Fastenal (FAST), First Horizon (FHN), Flir Systems (FLIR), ICU Medical (ICUI), Progressive (PGR),ProPetro Holding (PUMP), ServiceNow (NOW), SS&C (SSNC), SVB Financial (SIVB), UnitedHealth (UNH), and Weyerhaeuser (WY).

TODAY'S FREE FLY STORIES

MSFT

Microsoft

$105.08

-0.92 (-0.87%)

, DIS

Disney

$110.71

0.41 (0.37%)

07:35
07/19/18
07/19
07:35
07/19/18
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

MSFT

Microsoft

$105.08

-0.92 (-0.87%)

DIS

Disney

$110.71

0.41 (0.37%)

CZR

Caesars

$11.50

0.05 (0.44%)

RHT

Red Hat

$148.51

0.99 (0.67%)

OMC

Omnicom

$70.59

-0.1 (-0.14%)

FTI

TechnipFMC

$30.94

0.28 (0.91%)

ETFC

E-Trade

$63.14

2 (3.27%)

HLT

Hilton

$82.92

1.86 (2.29%)

BYD

Boyd Gaming

$37.89

-0.44 (-1.15%)

MT

ArcelorMittal

$30.99

0.665 (2.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 19

    Jul

  • 25

    Jul

  • 26

    Jul

  • 26

    Jul

  • 01

    Aug

  • 07

    Aug

  • 08

    Aug

  • 08

    Aug

  • 09

    Aug

  • 04

    Sep

AMZN

Amazon.com

$1,842.36

-1.64 (-0.09%)

, FB

Facebook

$209.35

-0.64 (-0.30%)

07:35
07/19/18
07/19
07:35
07/19/18
07:35
Recommendations
Amazon.com, Facebook, Twitter analyst commentary  »

JPMorgan continues to…

AMZN

Amazon.com

$1,842.36

-1.64 (-0.09%)

FB

Facebook

$209.35

-0.64 (-0.30%)

TWTR

Twitter

$43.34

-1.36 (-3.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

  • 27

    Jul

  • 16

    Aug

  • 18

    Sep

ADS

Alliance Data

$226.51

1.13 (0.50%)

07:34
07/19/18
07/19
07:34
07/19/18
07:34
Earnings
Breaking Earnings news story on Alliance Data »

Alliance Data reports Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

DPZ

Domino's Pizza

$283.74

1.74 (0.62%)

07:33
07/19/18
07/19
07:33
07/19/18
07:33
Hot Stocks
Domino's Pizza reports Q2 domestic SSS up 6.9% »

Reports Q2 international…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 21

    Sep

  • 05

    Oct

MNK

Mallinckrodt

$21.81

0.19 (0.88%)

07:33
07/19/18
07/19
07:33
07/19/18
07:33
Recommendations
Mallinckrodt analyst commentary  »

Mallinckrodt price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 08

    Aug

  • 09

    Aug

  • 13

    Aug

  • 22

    Aug

STBA

S&T Bancorp

$43.96

0.19 (0.43%)

07:33
07/19/18
07/19
07:33
07/19/18
07:33
Earnings
S&T Bancorp reports Q2 EPS 61c, consensus 61c »

Reports Q2 NIM 3.64%.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

ONDK

On Deck Capital

$8.09

0.6 (8.01%)

07:32
07/19/18
07/19
07:32
07/19/18
07:32
Downgrade
On Deck Capital rating change  »

Morgan Stanley sees On…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 08

    Aug

  • 15

    Aug

  • 16

    Aug

ADS

Alliance Data

$226.51

1.13 (0.50%)

07:32
07/19/18
07/19
07:32
07/19/18
07:32
Earnings
Breaking Earnings news story on Alliance Data »

Alliance Data backs FY18…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

ADS

Alliance Data

$226.51

1.13 (0.50%)

07:31
07/19/18
07/19
07:31
07/19/18
07:31
Earnings
Alliance Data backs FY18 core EPS view $22.50 to $23.00, consensus $22.57 »

CEO Heffernan continued:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

DPZ

Domino's Pizza

$283.74

1.74 (0.62%)

07:31
07/19/18
07/19
07:31
07/19/18
07:31
Earnings
Domino's Pizza reports Q2 adjusted EPS $1.84, consensus $1.75 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 21

    Sep

  • 05

    Oct

ADS

Alliance Data

$226.51

1.13 (0.50%)

07:30
07/19/18
07/19
07:30
07/19/18
07:30
Earnings
Alliance Data reports Q2 core EPS $5.01, consensus $4.66 »

Reports Q2 revenue $1.9B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

LONE

Lonestar Resources

$10.37

0.42 (4.22%)

07:30
07/19/18
07/19
07:30
07/19/18
07:30
Initiation
Lonestar Resources initiated  »

Lonestar Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

CMCSA

Comcast

$34.03

-0.23 (-0.67%)

, FOXA

21st Century Fox

$46.69

0.22 (0.47%)

07:30
07/19/18
07/19
07:30
07/19/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

CMCSA

Comcast

$34.03

-0.23 (-0.67%)

FOXA

21st Century Fox

$46.69

0.22 (0.47%)

GM

General Motors

$39.87

-0.185 (-0.46%)

PZZA

Papa John's

$53.60

2.06 (4.00%)

HPQ

HP Inc.

$23.54

-0.06 (-0.25%)

GOGO

Gogo

$3.91

0.15 (3.99%)

MDR

McDermott

$17.97

-0.075 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 27

    Jul

  • 31

    Jul

SQ

Square

$68.30

-0.02 (-0.03%)

07:28
07/19/18
07/19
07:28
07/19/18
07:28
Upgrade
Square rating change  »

Square upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 15

    Aug

  • 16

    Aug

MEET

Meet Group

$4.14

0.08 (1.97%)

07:26
07/19/18
07/19
07:26
07/19/18
07:26
Upgrade
Meet Group rating change  »

Meet Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$2.86

-0.1 (-3.38%)

07:26
07/19/18
07/19
07:26
07/19/18
07:26
Recommendations
Amarin analyst commentary  »

Amarin's Vascepa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$111.52

1.01 (0.91%)

07:25
07/19/18
07/19
07:25
07/19/18
07:25
Upgrade
JPMorgan rating change  »

JPMorgan upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

EBAY

eBay

$37.95

0.13 (0.34%)

07:25
07/19/18
07/19
07:25
07/19/18
07:25
Recommendations
eBay analyst commentary  »

eBay price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFIV

F5 Networks

$179.52

2.86 (1.62%)

07:24
07/19/18
07/19
07:24
07/19/18
07:24
Downgrade
F5 Networks rating change  »

Morgan Stanley sees risk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 08

    Aug

CMG

Chipotle

$453.56

0.77 (0.17%)

, SBUX

Starbucks

$51.15

-0.12 (-0.23%)

07:24
07/19/18
07/19
07:24
07/19/18
07:24
Recommendations
Chipotle, Starbucks analyst commentary  »

Wedbush cautious on…

CMG

Chipotle

$453.56

0.77 (0.17%)

SBUX

Starbucks

$51.15

-0.12 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 26

    Jul

PTCT

PTC Therapeutics

$35.02

-0.19 (-0.54%)

07:23
07/19/18
07/19
07:23
07/19/18
07:23
Initiation
PTC Therapeutics initiated  »

PTC Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRTX

Heron Therapeutics

$37.75

-0.35 (-0.92%)

07:22
07/19/18
07/19
07:22
07/19/18
07:22
Recommendations
Heron Therapeutics analyst commentary  »

Heron Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTB

M&T Bank

$174.38

5.77 (3.42%)

07:20
07/19/18
07/19
07:20
07/19/18
07:20
Recommendations
M&T Bank analyst commentary  »

M&T Bank price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:20
07/19/18
07/19
07:20
07/19/18
07:20
General news
Treasury Market Outlook: Treasury yields have extended slightly higher »

Treasury Market Outlook:…

WRD

WildHorse Resource

07:19
07/19/18
07/19
07:19
07/19/18
07:19
Initiation
WildHorse Resource initiated  »

WildHorse Resource…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 19

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.